Abstract
Tuberculosis remains a major health problem due to drug resistance and co-infection. Discovery of new drugs to counter tuberculosis is an urgent need. Multi-targeting strategy is one among the effective approach to combat the disease. Multi-targeting has minimal adverse effects. It is also difficult for Mycobacterium tuberculosis to survive and evolve into more drug-resistance strains in case of multi targeting. Lipases Rv0183 and Rv3802c were chosen as drug targets for the current study which are involved in the pathogen’s lipid and cell wall metabolism respectively. Seven potential dual inhibitors of tetrahydropyranyl and dibenzofuranone derivatives were discovered targeting respective substrate binding pocket of Rv0183 and Rv3802c. Molecule ZINC43860875 is the best hit with predicted free energy of binding (ΔG) of -10.80 and -10.97 kcal/mol against Rv0183 and Rv3802c respectively. Based on contact footprinting studies, several molecules were designed with better ΔG through modification of functional groups that favor van der Waals and ionic interactions. Molecule Rv0183-1 (combination of potential inhibitors ZINC43860875, ZINC28262919 and ZINC11616855) was identified as potential dual inhibitor against Rv0183 and Rv3802c with ΔG of - 18.08 and -16.14 kcal/mol respectively. The current study paves way towards design and development of new multi-target inhibitors to combat tuberculosis.
Keywords: Dual inhibitors, lipase, lipid metabolism, Rv0183, Rv3802c, tuberculosis.
Letters in Drug Design & Discovery
Title:Discovery of Potential Dual Inhibitors Against Lipases Rv0183 and Rv3802c for Tuberculosis Therapeutics
Volume: 13 Issue: 2
Author(s): Parameswaran Saravanan and Sanjukta Patra
Affiliation:
Keywords: Dual inhibitors, lipase, lipid metabolism, Rv0183, Rv3802c, tuberculosis.
Abstract: Tuberculosis remains a major health problem due to drug resistance and co-infection. Discovery of new drugs to counter tuberculosis is an urgent need. Multi-targeting strategy is one among the effective approach to combat the disease. Multi-targeting has minimal adverse effects. It is also difficult for Mycobacterium tuberculosis to survive and evolve into more drug-resistance strains in case of multi targeting. Lipases Rv0183 and Rv3802c were chosen as drug targets for the current study which are involved in the pathogen’s lipid and cell wall metabolism respectively. Seven potential dual inhibitors of tetrahydropyranyl and dibenzofuranone derivatives were discovered targeting respective substrate binding pocket of Rv0183 and Rv3802c. Molecule ZINC43860875 is the best hit with predicted free energy of binding (ΔG) of -10.80 and -10.97 kcal/mol against Rv0183 and Rv3802c respectively. Based on contact footprinting studies, several molecules were designed with better ΔG through modification of functional groups that favor van der Waals and ionic interactions. Molecule Rv0183-1 (combination of potential inhibitors ZINC43860875, ZINC28262919 and ZINC11616855) was identified as potential dual inhibitor against Rv0183 and Rv3802c with ΔG of - 18.08 and -16.14 kcal/mol respectively. The current study paves way towards design and development of new multi-target inhibitors to combat tuberculosis.
Export Options
About this article
Cite this article as:
Saravanan Parameswaran and Patra Sanjukta, Discovery of Potential Dual Inhibitors Against Lipases Rv0183 and Rv3802c for Tuberculosis Therapeutics, Letters in Drug Design & Discovery 2016; 13 (2) . https://dx.doi.org/10.2174/1570180812999150812165215
DOI https://dx.doi.org/10.2174/1570180812999150812165215 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
Call for Papers in Thematic Issues
Navigating the Frontier: Probiotics' Promising Path in Combatting Viral Respiratory Infections, Spotlight on Coronaviridae.
Probiotics, well-known for their role in gut health, show promise in preventing and managing respiratory virus infections, particularly in children and at-risk populations. However, the profound influence of novel pathogenic viral RTIs such as coronaviruses has reshaped perspectives on the potential of probiotics. Despite their potential, significant gaps remain in ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Biological Evaluation of Triazole-Vanillin Molecular Hybrids as Anti-Cancer Agents
Current Bioactive Compounds Synthetic Strategies and Biological Potential of Coumarin-Chalcone Hybrids: A New Dimension to Drug Design
Current Organic Chemistry Recent Advances in Azo Dye Degrading Enzyme Research
Current Protein & Peptide Science Multiscale Mapping of AIDS in U.S. Countries vs Anti-HIV Drugs Activity with Complex Networks and Information Indices
Current Bioinformatics <i>In Vivo</i> Anti-Candida Activity of <i>Artemisia herba alba</i> asso and <i>Citrus aurantium</i> Extracts Formulated in Different Ointments
Anti-Infective Agents Design of Anti-Bacterial Drug and Anti-Mycobacterial Drug for Drug Delivery System
Current Pharmaceutical Design Bacterial Transferase MraY, a Source of Inspiration towards New Antibiotics
Current Medicinal Chemistry Modification and Functionalization of Carboxylated Multiwall Nanotubes with Amantadine, Pregabalin and Alendronate Using Amidation as Anti Cancer Derivatives
Current Nanoscience Personalized and Predictive Medicine in Turkey: A Symposium Report of the Istanbul Working Group on Personalized Medicine, Istanbul, Turkey, September 10-12, 2009
Current Pharmacogenomics and Personalized Medicine Lactoferrin as a Natural Immune Modulator
Current Pharmaceutical Design The Case for Using Higher Doses of First Line Anti-Tuberculosis Drugs to Optimize Efficacy
Current Pharmaceutical Design Polymorphic Receptors of the Innate Immune System (MBL/MASP-2 and TLR2/4) and Susceptibility to Pneumococcal Bacteremia in HIV-Infected Patients: A Case-Control Study
Current HIV Research Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Medical and Societal Impact
Current Immunology Reviews (Discontinued) Fluoroquinolones as Chemotherapeutics Against Mycobacterial Infections
Current Pharmaceutical Design Anti-Bacterial
Current Bioactive Compounds Stimulator of Interferon Genes Signaling Pathway and its Role in Anti-tumor Immune Therapy
Current Pharmaceutical Design Bioactive Chemical Entities: Pre-Clinical and Clinical Aspects - Part-VIII
Current Topics in Medicinal Chemistry Monoclonal Antibodies Carried in Drug Delivery Nanosystems as a Strategy for Cancer Treatment
Current Medicinal Chemistry An Overview of Various Rifampicin Analogs against <i>Mycobacterium tuberculosis</i> and their Drug Interactions
Medicinal Chemistry Medicinal and Beneficial Health Applications of Tinospora cordifolia (Guduchi): A Miraculous Herb Countering Various Diseases/Disorders and its Immunomodulatory Effects
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)